Kola Karim Appointed as Chairman of BAT Nigeria's Advisory Committee

Business by 2FIRSTS.ai

Nov.29.2023

Kola Karim Appointed as Chairman of BAT Nigeria's Advisory Committee

Kola Karim, the current Agbaoye of Ibadan, will take over as the Chairman of BAT Nigeria's Advisory Council from November 1, 2023.

British American Tobacco Nigeria (BAT Nigeria) has announced that Kola Karim will assume the role of Chairman of its Advisory Committee starting from November 1, 2023. Currently, Karim serves as the Agbaoye of Ibadan land and holds a managerial position within the company.

References:

[1] BAT Nigeria appoints Karim advisory board chairman

Also Read:

[1] BAT Korea and PMI Seek Expansion in South Korean E-cigarette Market

[2] BAT Opens E-Cigarette Pop-Up Store in Seoul's Saensu District

#Personnel appointment #British American Tobacco (BAT)

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

XQS Rolls Out Two Beverage-Flavoured Nicotine Pouches in UK; Says Convenience Stores Are the Fastest-Growing Channel

Scandinavian Tobacco Group (STG) UK has added two beverage-inspired variants—Cola Lime and Fizzy Peach—to its XQS nicotine pouch range. Both come in an 8mg strength and are available exclusively via the Vape Supplier website, with a recommended retail price of £5.50.

Oct.29 by 2FIRSTS.ai

84% of Britons Back Regulation of Nicotine Pouches, Survey Finds

A Northerner survey finds 84% of Britons support regulating nicotine pouches and 82% back a licensing scheme for vape sales, aligning with the Tobacco and Vapes Bill to improve consumer safety and youth protection.

Nov.06 by 2FIRSTS.ai

SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores

According to an SKE release published on PR Newswire, the company is expanding its presence in the Korean market through convenience store and specialty retail channels. SKE has partnered with 7-Eleven Korea, placing its products in more than 5,700 stores nationwide, and is also working with OG9’s offline retail and B2B distribution network. On the product side, SKE is focusing on promoting the Crystal Bar TB1000 and Cloud Zero in Korea.

Nov.19 by 2FIRSTS.ai

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st